Intarcia was one of the high-flying companies that emerged from the investment money that flooded into small biotechnology companies in the 2010s. Its strategy was to outmaneuver the makers of weekly glucose-lowering shots called GLP-1s — Eli Lilly with Trulicity and Novo Nordisk with Ozempic — by offering a product that could have the same benefit for a year.
In addition to lowering blood sugar, drugs in this class have also been approved for weight-loss in overweight and obese people.
